Prognostic significance of Sox4 expression in human cutaneous melanoma and its role in cell migration and invasion

American Journal of Pathology

Volumn 177, Issue 6, 2010, Pages 2741-2752

  Jafarnejad, Seyed Mehdi ^a   Wani, Aijaz Ahmad ^a   Martinka, Magdalena ^a   Li, Gang ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR SOX4;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STRESS FIBER; TISSUE MICROARRAY;

EID: 78650198694     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.100377     Document Type: Article

References (61)

1. Chin L, Garraway LA, Fisher DE: Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006, 20:2149-2182 (Pubitemid 44244518)
2. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, Chanmugam A: Cutaneous malignant melanoma. Mayo Clin Proc 2006, 81:500-507
3. Gray-Schopfer V, Wellbrock C, Marais R: Melanoma biology and new targeted therapy. Nature 2007, 445:851-857 (Pubitemid 46309849)
4. Miller AJ, Mihm MC, Jr.: Melanoma. N Engl J Med 2006, 355:51-65
5. Schepers GE, Teasdale RD, Koopman P: Twenty pairs of sox: extent, homology, and nomenclature of the mouse and human sox transcription factor gene families. Dev Cell 2002, 3:167-170
6. Bowles J, Schepers G, Koopman P: Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. Dev Biol 2000, 227:239-255
7. Wegner M: From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res 1999, 27:1409-1420
8. Kiefer JC: Back to basics: sox genes. Dev Dyn 2007, 236:2356-2366
9. Lefebvre V, Dumitriu B, Penzo-Mendez A, Han Y, Pallavi B: Control of cell fate and differentiation by Sry-related high-mobility-group box (Sox) transcription factors. Int J Biochem Cell Biol 2007, 39:2195-2214 (Pubitemid 47484275)
10. Wang Q, He W, Lu C, Wang Z, Wang J, Giercksky KE, Nesland JM, Suo Z: Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma. Anticancer Res 2009, 29:1233-1241
11. Nonaka D: Differential expression of SOX2 and SOX17 in testicular germ cell tumors. Am J Clin Pathol 2009, 131:731-736
12. Lu B, Fang Y, Xu J, Wang L, Xu F, Xu E, Huang Q, Lai M: Analysis of SOX9 expression in colorectal cancer. Am J Clin Pathol 2008, 130:897-904
13. Farr CJ, Easty DJ, Ragoussis J, Collignon J, Lovell-Badge R, Goodfellow PN: Characterization and mapping of the human SOX4 gene. Mamm Genome 1993, 4:577-584
14. van de Wetering M, Oosterwegel M, van Norren K, Clevers H: Sox-4, an Sry-like HMG box protein, is a transcriptional activator in lymphocytes. EMBO J 1993, 12:3847-3854
15. Penzo-Mendez AI: Critical roles for SoxC transcription factors in development and cancer. Int J Biochem Cell Biol 2010, 42:425-428
16. Bangur CS, Switzer A, Fan L, Marton MJ, Meyer MR, Wang T: Identification of genes over-expressed in small cell lung carcinoma using suppression subtractive hybridization and cDNA microarray expression analysis. Oncogene 2002, 21:3814-3825
17. Frierson HF, Jr., El-Naggar AK, Welsh JB, Sapinoso LM, Su AI, Cheng J, Saku T, Moskaluk CA, Hampton GM: Large scale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma. Am J Pathol 2002, 161:1315-1323
18. de Bont JM, Kros JM, Passier MM, Reddingius RE, Sillevis Smitt PA, Luider TM, den Boer ML, Pieters R: Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis. Neuro Oncol 2008, 10:648-660
19. Liu P, Ramachandran S, Ali Seyed M, Scharer CD, Laycock N, Dalton WB, Williams H, Karanam S, Datta MW, Jaye DL, Moreno CS: Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 2006, 66:4011-4019
20. Pramoonjago P, Baras AS, Moskaluk CA: Knockdown of Sox4 expression by RNAi induces apoptosis in ACC3 cells. Oncogene 2006, 25:5626-5639 (Pubitemid 44387618)
21. Huang YW, Liu JC, Deatherage DE, Luo J, Mutch DG, Goodfellow PJ, Miller DS, Huang TH: Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res 2009, 69:9038-9046
22. Aaboe M, Birkenkamp-Demtroder K, Wiuf C, Sorensen FB, Thykjaer T, Sauter G, Jensen KM, Dyrskjot L, Orntoft T: SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res 2006, 66:3434-3442
23. Ahn SG, Kim HS, Jeong SW, Kim BE, Rhim H, Shim JY, Kim JW, Lee JH, Kim IK: Sox-4 is a positive regulator of Hep3B and HepG2 cells' apoptosis induced by prostaglandin (PG)A(2) and delta(12)-PGJ(2). Exp Mol Med 2002, 34:243-249
24. Hur EH, Hur W, Choi JY, Kim IK, Kim HY, Yoon SK, Rhim H: Functional identification of the pro-apoptotic effector domain in human Sox4. Biochem Biophys Res Commun 2004, 325:59-67
25. Pan X, Zhao J, Zhang WN, Li HY, Mu R, Zhou T, Zhang HY, Gong WL, Yu M, Man JH, Zhang PJ, Li AL, Zhang XM: Induction of SOX4 by DNA damage is critical for p53 stabilization and function. Proc Natl Acad Sci USA 2009, 106:3788-3793
26. Byers HR, Etoh T, Doherty JR, Sober AJ, Mihm MC, Jr.: Cell migration and actin organization in cultured human primary, recurrent cutaneous and metastatic melanoma. Time-lapse and image analysis. Am J Pathol 1991, 139:423-435
27. Wang Y, Li G: ING3 promotes UV-induced apoptosis via Fas/caspase-8 pathway in melanoma cells. J Biol Chem 2006, 281:11887-11893
28. Gao K, Dai DL, Martinka M, Li G: Prognostic significance of nuclear factor-kappaB p105/p50 in human melanoma and its role in cell migration. Cancer Res 2006, 66:8382-8388
29. Wong RP, Ng P, Dedhar S, Li G: The role of integrin-linked kinase in melanoma cell migration, invasion, and tumor growth. Mol Cancer Ther 2007, 6:1692-1700 (Pubitemid 46954045)
30. Friedl P, Wolf K: Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003, 3:362-374
31. Condeelis J, Singer RH, Segall JE: The great escape: when cancer cells hijack the genes for chemotaxis and motility. Annu Rev Cell Dev Biol 2005, 21:695-718
32. Scharer CD, McCabe CD, Ali-Seyed M, Berger MF, Bulyk ML, Moreno CS: Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. Cancer Res 2009, 69:709-717
33. Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, Ravetti GL, Zona GL, Daga A, Corte G: SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 2009, 27:40-48
34. Huang DY, Lin YT, Jan PS, Hwang YC, Liang ST, Peng Y, Huang CY, Wu HC, Lin CT: Transcription factor SOX-5 enhances nasopharyngeal carcinoma progression by down-regulating SPARC gene expression. J Pathol 2008, 214:445-455
35. Pan X, Li H, Zhang P, Jin B, Man J, Tian L, Su G, Zhao J, Li W, Liu H, Gong W, Zhou T, Zhang X: Ubc9 interacts with SOX4 and represses its transcriptional activity. Biochem Biophys Res Commun 2006, 344:727-734
36. Boyd KE, Xiao YY, Fan K, Poholek A, Copeland NG, Jenkins NA, Perkins AS: Sox4 cooperates with Evi1 in AKXD-23 myeloid tumors via transactivation of proviral LTR. Blood 2006, 107:733-741 (Pubitemid 43076400)
37. Wang H, Leav I, Ibaragi S, Wegner M, Hu GF, Lu ML, Balk SP, Yuan X: SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res 2008, 68:1625-1630
38. Passeron T, Valencia JC, Namiki T, Vieira WD, Passeron H, Miyamura Y, Hearing VJ: Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid. J Clin Invest 2009, 119:954-963
39. Gupta GP, Massague J: Cancer metastasis: building a framework. Cell 2006, 127:679-695
40. Hur W, Rhim H, Jung CK, Kim JD, Bae SH, Jang JW, Yang JM, Oh ST, Kim DG, Wang HJ, Lee SB, Yoon SK: SOX4 overexpression regulates the p53-mediated apoptosis in hepatocellular carcinoma: clinical implication and functional analysis in vitro, Carcinogenesis 31:1298-1307
41. Bollrath J, Greten FR: IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep 2009, 10:1314-1319
42. Shen HM, Tergaonkar V: NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 2009, 14:348-363
43. Perkins ND: NF-kappaB: tumor promoter or suppressor? Trends Cell Biol 2004, 14:64-69
44. Amiri KI, Richmond A: Role of nuclear factor-kappa B in melanoma. Cancer Metastasis Rev 2005, 24:301-313
45. van de Stolpe A, Caldenhoven E, Stade BG, Koenderman L, Raaijmakers JA, Johnson JP, van der Saag PT: 12-O-tetradecanoylphorbol-13-acetate- and tumor necrosis factor alpha-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 promoter. J Biol Chem 1994, 269:6185-6192
46. Yamazaki D, Kurisu S, Takenawa T: Regulation of cancer cell motility through actin reorganization. Cancer Sci 2005, 96:379-386 (Pubitemid 41179738)
47. Cogswell PC, Scheinman RI, Baldwin AS, Jr.: Promoter of the human NF-kappa B p50/p105 gene. Regulation by NF-kappa B subunits and by c-REL. J Immunol 1993, 150:2794-2804
48. Wilson M, Koopman P: Matching SOX: partner proteins and cofactors of the SOX family of transcriptional regulators. Curr Opin Genet Dev 2002, 12:441-446
49. Kamachi Y, Uchikawa M, Kondoh H: Pairing SOX off: with partners in the regulation of embryonic development. Trends Genet 2000, 16:182-187
50. Latonen L, Laiho M: Cellular UV damage responses-functions of tumor suppressor p53. Biochim Biophys Acta 2005, 1755:71-89
51. Park HY, Kosmadaki M, Yaar M, Gilchrest BA: Cellular mechanisms regulating human melanogenesis. Cell Mol Life Sci 2009, 66:1493-1506
52. Gilchrest BA, Eller MS, Geller AC, Yaar M: The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999, 340:1341-1348
53. Atillasoy ES, Seykora JT, Soballe PW, Elenitsas R, Nesbit M, Elder DE, Montone KT, Sauter E, Herlyn M: UVB induces atypical melanocytic lesions and melanoma in human skin. Am J Pathol 1998, 152:1179-1186
54. Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, Jacks T: Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009, 462:104-107
55. Chin L, Merlino G, DePinho RA: Malignant melanoma: modern black plague and genetic black box. Genes Dev 1998, 12:3467-3481
56. Hartmann A, Blaszyk H, Cunningham JS, McGovern RM, Schroeder JS, Helander SD, Pittelkow MR, Sommer SS, Kovach JS: Overexpression and mutations of p53 in metastatic malignant melanomas. Int J Cancer 1996, 67:313-317 (Pubitemid 26274118)
57. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C, Lowe SW: Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001, 409:207-211
58. Monzon J, Liu L, Brill H, Goldstein AM, Tucker MA, From L, McLaughlin J, Hogg D, Lassam NJ: CDKN2A mutations in multiple primary melanomas. N Engl J Med 1998, 338:879-887
59. Sinner D, Kordich JJ, Spence JR, Opoka R, Rankin S, Lin SC, Jonatan D, Zorn AM, Wells JM: Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol Cell Biol 2007, 27:7802-7815
60. Larue L, Delmas V: The WNT/Beta-catenin pathway in melanoma. Front Biosci 2006, 11:733-742
61. Crampton SP, Wu B, Park EJ, Kim JH, Solomon C, Waterman ML, Hughes CC: Integration of the beta-catenin-dependent Wnt pathway with integrin signaling through the adaptor molecule Grb2. PLoS One 2009, 4:e7841